- Home
- ENSC vs SISI Comparison
ENSC vs SISI Comparison
Compare ENSC & SISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- SISI
- Stock Information
- Founded
- ENSC 2003
- SISI 1997
- Country
- ENSC United States
- SISI China
- Employees
- ENSC N/A
- SISI N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- SISI Medicinal Chemicals and Botanical Products
- Sector
- ENSC Health Care
- SISI Health Care
- Exchange
- ENSC Nasdaq
- SISI Nasdaq
- Market Cap
- ENSC 6.4M
- SISI 5.6M
- IPO Year
- ENSC N/A
- SISI 2016
- Fundamental
- Price
- ENSC $2.27
- SISI $5.60
- Analyst Decision
- ENSC
- SISI
- Analyst Count
- ENSC 0
- SISI 0
- Target Price
- ENSC N/A
- SISI N/A
- AVG Volume (30 Days)
- ENSC 149.6K
- SISI 97.6K
- Earning Date
- ENSC 11-11-2025
- SISI 11-13-2025
- Dividend Yield
- ENSC N/A
- SISI N/A
- EPS Growth
- ENSC N/A
- SISI N/A
- EPS
- ENSC N/A
- SISI N/A
- Revenue
- ENSC $7,413,722.00
- SISI $9,601,324.00
- Revenue This Year
- ENSC N/A
- SISI N/A
- Revenue Next Year
- ENSC $1,354.55
- SISI N/A
- P/E Ratio
- ENSC N/A
- SISI N/A
- Revenue Growth
- ENSC 415.58
- SISI 1133.26
- 52 Week Low
- ENSC $1.62
- SISI $1.00
- 52 Week High
- ENSC $14.67
- SISI $271.50
- Technical
- Relative Strength Index (RSI)
- ENSC 51.69
- SISI 43.37
- Support Level
- ENSC $2.35
- SISI $5.42
- Resistance Level
- ENSC $2.63
- SISI $6.27
- Average True Range (ATR)
- ENSC 0.19
- SISI 0.61
- MACD
- ENSC 0.01
- SISI -0.04
- Stochastic Oscillator
- ENSC 34.60
- SISI 12.49
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.